title: Efficacy of cilostazol in patients with acute coronary syndrome after percutaneous coronary intervention.
abstract: The objective of this study was to explore the long-term effect of cilostazol-optimized antiplatelet therapy after percutaneous coronary intervention (PCI) in patients with acute coronary syndrome (ACS). One hundred forty-six patients with ACS who underwent PCI were enrolled. Patients were randomly divided into 2 groups based on clot rate (CR), and both groups received antiplatelet therapy: aspirin and clopidogrel plus cilostazol (intensification group, n = 72) or aspirin and clopidogrel (control group, n = 74). Clinical follow-up was up to 12 months after PCI. During follow-up, CR was determined at day 1 and at 1, 3, 6, and 12 months post-PCI. Efficacy endpoints included second acute myocardial infarction, in-stent thrombosis, revascularization (second PCI), sudden death, and hemorrhage. CR was significantly lower in the intensification group than in the control group at 1, 3, and 6 months after PCI (P < 0.05). The incidences of second acute myocardial infarction, in-stent thrombosis, revascularization (second PCI), and sudden cardiac death were also lower but insignificant; there were no hemorrhage events (P > 0.05). Cilostazol-optimized antiplatelet therapy can significantly decrease CR after PCI in patients with acute coronary syndrome.
authors.affiliation: Department of Cardiology, Second Affiliated Hospital of Wuhan University, Wuhan, China.
authors.forename: Taohong
authors.initials: T
authors.lastname: Hu
authors.forename: Huili
authors.initials: H
authors.lastname: Ma
authors.forename: Huijun
authors.initials: H
authors.lastname: Li
authors.forename: Jianghua
authors.initials: J
authors.lastname: Ren
mesh_terms: D054058:Acute Coronary Syndrome / Q000628:therapy*; D000368:Aged; D000369:Aged, 80 and over; D001241:Aspirin / Q000008:administration & dosage / Q000627:therapeutic use; D001777:Blood Coagulation / Q000187:drug effects; D000077407:Cilostazol; D000077144:Clopidogrel; D003131:Combined Modality Therapy; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D062645:Percutaneous Coronary Intervention / Q000379:methods*; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D013777:Tetrazoles / Q000008:administration & dosage / Q000627:therapeutic use*; D013988:Ticlopidine / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D010975:Platelet Aggregation Inhibitors; D013777:Tetrazoles; D000077144:Clopidogrel; D000077407:Cilostazol; D013988:Ticlopidine; D001241:Aspirin